Dr Katy Bell

Honorary Senior Lecturer
Public Health, School of Public Health

Telephone 0415 764 321
Fax 9351 7420

Map

Selected grants

2006

  • Screening and Test Evaluation Program (STEP); Bell K, Irwig L, Craig J, Salkeld G, Macaskill P; National Health and Medical Research Council (NHMRC)/Program Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Bell, K., Craig, J., Irwig, L. (2008). Monitoring the initial response to treatment. In P Glasziou, L Irwig and J K Aronson (Eds.), Evidence-based Medical Monitoring:From Principles to Practice, (pp. 75-89). Oxford: Blackwell Publishers.

Journals

  • Bell, K., Glasziou, P., Hayen, A., Irwig, L. (2014). Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. Journal of Clinical Epidemiology, 67(2), 152-159. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Takahashi, O., Ohde, S., Glasziou, P. (2013). When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ, 346(7906), 1-8. [More Information]
  • Hayden, A., Bell, K., Glasziou, P., Irwig, L. (2012). A counterargument to encounter frequency and target achievement: measurement variability. Archives of Internal Medicine, 172(4), 374-375. [More Information]
  • Bell, K., Hayen, A., McGeechan, K., Neal, B., Irwig, L. (2012). Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 19(6), 1474-1485. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Hochberg, M., Ensrud, K., Cummings, S., Bauer, D. (2012). The Potential Value of Monitoring Bone Turnover Markers Among Women on Alendronate. Journal of Bone and Mineral Research, 27(1), 195-201. [More Information]
  • Bell, K., Kirby, A., Hayen, A., Irwig, L., Glasziou, P. (2011). Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ: British Medical Journal, 342(Issue 7791, 29 January 2011, Article number d12), 1-7. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]
  • Hayen, A., Bell, K., Glasziou, P., Neal, B., Irwig, L. (2010). Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension, 56(4), 612-616. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Fox, K., Remme, W., Asselbergs, F., van Gilst, W., MacMahon, S., Irwig, L., et al (2010). Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials. Hypertension, 56(3), 533-539. [More Information]
  • Bell, K., Irwig, L., Hayen, A., Macaskill, P., Craig, J. (2010). Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiology and drug safety, 19(1), 99-105. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Macaskill, P., Craig, J., Ensrud, K., Bauer, D. (2010). The Value of Routine BMD Monitoring After Starting Bisphosphonate Treatment. Journal of Bone and Mineral Research, 25(1), 173-174. [More Information]
  • Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. Asia-Pacific Journal of Clinical Oncology, 5(4), 257-263. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Irwig, L. (2009). Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. Journal of Clinical Epidemiology, 62, 650-659. [More Information]
  • Lincz, L., Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology, 90(1), 136-140. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Irwig, L., Craig, J., Ensrud, K., Bauer, D. (2009). Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ: British Medical Journal, 338(b2266), b2266-1-b2266-5. [More Information]
  • Bell, K., Irwig, L., Craig, J., Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ: British Medical Journal, 336, 361-365. [More Information]
  • Bell, K., Wattie, M., Byth Wilson, K., Silvestrini, R., Clark, P., Stachowski, E., Benson, E. (2003). Procalcitonin: A marker of bacteraemia is SIRS. Anaesthesia and Intensive Care, 31(6), 629-636.

2014

  • Bell, K., Glasziou, P., Hayen, A., Irwig, L. (2014). Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. Journal of Clinical Epidemiology, 67(2), 152-159. [More Information]

2013

  • Bell, K., Hayen, A., Irwig, L., Takahashi, O., Ohde, S., Glasziou, P. (2013). When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ, 346(7906), 1-8. [More Information]

2012

  • Hayden, A., Bell, K., Glasziou, P., Irwig, L. (2012). A counterargument to encounter frequency and target achievement: measurement variability. Archives of Internal Medicine, 172(4), 374-375. [More Information]
  • Bell, K., Hayen, A., McGeechan, K., Neal, B., Irwig, L. (2012). Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 19(6), 1474-1485. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Hochberg, M., Ensrud, K., Cummings, S., Bauer, D. (2012). The Potential Value of Monitoring Bone Turnover Markers Among Women on Alendronate. Journal of Bone and Mineral Research, 27(1), 195-201. [More Information]

2011

  • Bell, K., Kirby, A., Hayen, A., Irwig, L., Glasziou, P. (2011). Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ: British Medical Journal, 342(Issue 7791, 29 January 2011, Article number d12), 1-7. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]

2010

  • Hayen, A., Bell, K., Glasziou, P., Neal, B., Irwig, L. (2010). Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension, 56(4), 612-616. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Fox, K., Remme, W., Asselbergs, F., van Gilst, W., MacMahon, S., Irwig, L., et al (2010). Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials. Hypertension, 56(3), 533-539. [More Information]
  • Bell, K., Irwig, L., Hayen, A., Macaskill, P., Craig, J. (2010). Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiology and drug safety, 19(1), 99-105. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Macaskill, P., Craig, J., Ensrud, K., Bauer, D. (2010). The Value of Routine BMD Monitoring After Starting Bisphosphonate Treatment. Journal of Bone and Mineral Research, 25(1), 173-174. [More Information]

2009

  • Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. Asia-Pacific Journal of Clinical Oncology, 5(4), 257-263. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Irwig, L. (2009). Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. Journal of Clinical Epidemiology, 62, 650-659. [More Information]
  • Lincz, L., Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology, 90(1), 136-140. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Irwig, L., Craig, J., Ensrud, K., Bauer, D. (2009). Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ: British Medical Journal, 338(b2266), b2266-1-b2266-5. [More Information]

2008

  • Bell, K., Craig, J., Irwig, L. (2008). Monitoring the initial response to treatment. In P Glasziou, L Irwig and J K Aronson (Eds.), Evidence-based Medical Monitoring:From Principles to Practice, (pp. 75-89). Oxford: Blackwell Publishers.
  • Bell, K., Irwig, L., Craig, J., Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ: British Medical Journal, 336, 361-365. [More Information]

2003

  • Bell, K., Wattie, M., Byth Wilson, K., Silvestrini, R., Clark, P., Stachowski, E., Benson, E. (2003). Procalcitonin: A marker of bacteraemia is SIRS. Anaesthesia and Intensive Care, 31(6), 629-636.

To update your profile click here. For support on your academic profile contact .